

Dr. Thomas Felix is a R&D Policy Director in Amgen's Global Regulatory Affairs and Safety organization. He has worked at the company since 2006. As Amgen develops its biosimilars, Dr. Felix contributes to a cross-functional, multidisciplinary team committed to advancing science and policy for a successful, patient-focused implementation. Dr. Felix interacts with private/public payers, medical societies, and leaders from various therapeutic areas to help inform and shape biosimilar policy in the US. He serves as a subject matter expert, informing US State governments on necessary legislative provisions to allow for science-based substitution of biosimilars in the retail pharmacy setting. Dr. Felix also contributes to the advancement of pharmacovigilance (PV) systems to more accurately identify adverse events in a timely manner. He partners with internal and external pharmacovigilance experts to better understand the ability to track and trace multisource therapeutics in various treatment settings and regions.

Dr. Felix earned his medical degree at the PSG Institute of Medical Sciences and Research (India). Prior to Amgen, Dr. Felix was Vice-President of Medical Affairs at an NBC Universal health media company (Healthology, Inc., New York, NY), an organization dedicated to the development of physician-led educational programs on disease management across therapeutic areas. Prior to that, Dr. Felix worked at Aventis Pharmaceuticals (Bridgewater, NJ) as a member of the medical team dedicated to studying and sharing the appropriate use of anticoagulant therapy enoxaparin sodium (Lovenox®).